Results 51 to 60 of about 4,926,176 (337)

Incidence and Outcome of Infants With Cancer in Canada: A Report From Cancer in Young People in Canada Database

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Purpose Infants with cancer are rare and face unique challenges. Our study aims to describe the incidence of infantile cancers in Canada and to compare treatment‐related mortality (TRM) and their outcomes with those of older children. Methods We conducted a retrospective cohort study using the Cancer in Young People in Canada database ...
Samuel Sassine, Hallie Coltin, Maria Kondyli, Monia Marzouki, Nicolas Prud'homme, Nida Usmani, Sylvia Cheng, Lesleigh Abbott, Tony Truong, Sapna Oberoi, Ketan Kulkarni, Josée Brossard, Lynette Bowes, Paul Gibson, Donna L. Johnston, Sarah McKillop, Roona Sinha, Lillian Sung, Catherine Vezina, Laura Wheaton, Alexandra P. Zorzi, Marie‐Claude Pelland‐Marcotte, Thai Hoa Tran   +22 more
wiley   +1 more source

Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017

JAMA Network Open, 2020
Key Points Question Have the number and characteristics of pivotal efficacy trials supporting US Food and Drug Administration approval of new drugs and biologics changed during the past 3 decades?
A. Zhang, Jeremy Puthumana, Nicholas Downing, N. Shah, H. Krumholz, J. Ross   +5 more
semanticscholar   +1 more source

Safety and Efficacy of Anticoagulation Therapy in Paediatric Patients With Solid Tumours or Lymphomas at Risk of Thrombocytopenia: A Retrospective Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Patients with solid tumours or lymphomas have an increased risk of thromboembolism (TE) and thrombocytopenia. Evidence‐based strategies for anticoagulation therapy (ACT) for patients with thrombocytopenia are limited. We examined the impact of thrombocytopenia on ACT administration and bleeding incidence in children with solid ...
Andrés Felipe Fajardo, Katherine Talpin, Bishal Harry, Uma H. Athale, Anthony K. C. Chan, Mihir D. Bhatt   +5 more
wiley   +1 more source

Factors Affecting Drug‐Development Strategies in Asian Global Clinical Trials for Drug Approval in Japan

Clinical and Translational Science, 2017
We assessed the current status of Asian global clinical trials (GCTs) and factors, such as therapeutic areas, main metabolic enzymes targeted, approval status in the United States or the European Union, development strategies, influencing drug ...
K. Asano, Y. Uyama, M. Tohkin
semanticscholar   +1 more source

Survival for Children Diagnosed With Wilms Tumour (2012–2022) Registered in the UK and Ireland Improving Population Outcomes for Renal Tumours of Childhood (IMPORT) Study

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background The Improving Population Outcomes for Renal Tumours of childhood (IMPORT) is a prospective clinical observational study capturing detailed demographic and outcome data on children and young people diagnosed with renal tumours in the United Kingdom and the Republic of Ireland.
Naomi Ssenyonga, Angela Lopez‐Cortes, Reem Al‐Saadi, Suzanne Tugnait, Kristina Dzhuma, Catriona Duncan, Gordan Vujanic, Tanzina Chowdhury, Claudia Allemani, Michel P. Coleman, Kathy Pritchard‐Jones, the Children's Cancer and Leukaemia Group (CCLG) Renal Tumour Special Interest Group, Hugh Bishop, Anthony McCarthy, Pamela Kearns, Helen Rees, Amos Burke, Meriel Jenney, Jane Pears, Hamish Wallace, Milind Ronghe, Tanzina Chowdhury, Susan Picton, Emma Ross, Lisa Howell, Bernadette Brennan, Gail Halliday, Richard Grundy, Shaun Wilson, Sucheta Vaidya, Daniel Yeomanson, Jessica Bate, Vesna Pavasovic, Jessica Bate, Sabine Irtan, Jesper Brok, Minou Oostveen, Kristina Dzhuma, Mark Weeks, Richard Williams, Mark Powis, Max Pachl, Bruce Okoye, Naima Smeulders, Gordan Vujanic, Oystein Olsen, Tom Watson, Susan Shelmerdine, Dan Saunders, Angela Lopez-Cortes, Taryn Treger, Tom Jackson, Suzanne Tugnait, Lisa Howell, Tanzina Chowdhury, Sam Behjati, Angela Polanco   +56 more
wiley   +1 more source

Participation of African American Persons in Clinical Trials Supporting U.S. Food and Drug Administration Approval of Cancer Drugs

Annals of Internal Medicine, 2020
Supporting U.S. Food and Drug Administration Approval of Cancer Drugs Background: In the United States, African American persons have the highest death rate and lowest survival rate of any racial or ethnic group for most types of cancer.
Samer Al Hadidi, M. Mims, C. Miller-Chism, R. Kamble   +3 more
semanticscholar   +1 more source

Preoperative Cytopenia in Patients Affected by High‐Risk Neuroblastoma: Just a Matter of Platelets?

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background and Aims In patients affected by high‐risk neuroblastoma (HR‐NB), complete macroscopic resection (CMR) is associated with better outcomes. These patients are often cytopenic due to intensive induction regimens. The aim of the present study is to assess the impact of preoperative cytopenia on surgical outcome in patients with HR‐NB ...
Giorgio Persano, Valerio Voglino, Federico Beati, Cristina Martucci, Chiara Grimaldi, Francesca Del Bufalo, Annalisa Serra, Francesco Fabozzi, Carmen Malaspina, Pier Luigi Di Paolo, Gian Luigi Natali, Simone Reali, Maria Antonietta De Ioris, Alessandro Crocoli   +13 more
wiley   +1 more source

Drug approval processes: A case study of rivaroxaban

Archives of Pharmacy Practice, 2013
Rivaroxaban, a Xa inhibitor, was recently approved (March 2013) in the setting of post-acute coronary syndromes (ACS) by the European Medicine Agency. This is in contrast to not being approved by the Food and Drug Agency in the United States for the same
Sally A Arif, Zainab Bilfaqi
doaj   +1 more source

What to Do When Medical Evidence Can Only Be Generated Through Routine Data: An Example From Pediatric Oncology

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Children undergoing allogeneic stem cell transplantation often receive off‐label rituximab treatment for Epstein–Barr virus reactivation, using adult dosing without pediatric evidence. This project aims to develop a clinical decision support tool (CDSS) that provides evidence‐based dosing scenarios by analyzing real‐world patient data.
Birgit Burkhardt, Antje Walz, Dietrich Knoerzer   +2 more
wiley   +1 more source

An empirical analysis of overall survival in drug approvals by the US FDA (2006–2023)

Cancer Medicine
Background The US Food and Drug Administration (FDA) has expanded the use of surrogate markers in drugs approved for oncology/hematology indications. This has likely resulted in a greater number of approvals and possibly drugs coming to market faster ...
Josh Elbaz, Alyson Haslam, Vinay Prasad
doaj   +1 more source